tag diversity 
Medical Xpress
MARCH 8, 2023
Failure to enroll enough participants in trials can delay the arrival of new therapies in the clinic and inflate their eventual price tags. Failure to recruit diverse patients could diminish the relevance and generalizability of trial findings.
Rethinking Clinical Trials
DECEMBER 20, 2023
Diversity in clinical trials is important for generalizability of results, to provide equal opportunities, practice precision medicine, tailor practical guidelines, improve public health outcomes, detect potential differences in safety and efficacy, and to address health disparities. We need to think about removing some of this and evaluate.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
AUGUST 23, 2022
Diversity, Inclusion. There is a national priority to increase diversity in clinical trials, from regulatory, funding agencies, industry, and others, so that the participant population reflects the U.S. population at large, which is steadily becoming more diverse. Duke University School of Medicine. Key Points. Learn more.
Rethinking Clinical Trials
MAY 10, 2023
The program will nurture partnerships for decades with at least a million participants who reflect the diversity of the U.S.; Participation in All of Us is open to all and reflects the rich diversity of the U.S. By the end of 2026, the goal is to reach 1 million participants who reflect the diversity of the U.S.,
Rethinking Clinical Trials
NOVEMBER 1, 2022
The HERO Registry aimed to create a diverse virtual community of healthcare workers and their families and communities, ready for future COVID-19 research. The HERO Program was fully approved and began recruiting participants on April 22, 2020. pctGR, @Collaboratory1.
Rethinking Clinical Trials
JULY 27, 2022
One thing that has been a struggle is the diversity in the population and the equity in access to trials. We did not see as much diversity in this decentralized trial. The sites had a very clear role, and the training was really important. There was a lot of outreach to sites and they embraced the remote trial. pctGR, @Collaboratory1.
Pharmaceutical Technology
MAY 2, 2023
IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000. There is currently a rich and diverse IO pipeline that aims to address these unmet needs, with 703 IO products currently in clinical trials. Cost-related unmet needs also scored highly.
Expert insights. Personalized for you.
105 
Let's personalize your content